Patients with significant medical conditions, history of chronic insulin treatment, use of corticosteroids, or recent use of investigational medications will be excluded. Patients must normally eat 3 meals daily, and must agree to maintain prior exercise and diet habits during the study.
Visits occur at the beginning and end of the screening period.
At the first and final study visits, patients will be administered tablets prior to a standard meal and after all laboratory samples have been obtained. A fingerstick blood glucose level will be performed 2 hours after the start of the meal to assess 2 hour post-meal glucose. Study tablets must be taken 1-30 minutes prior to 3 regularly scheduled meals daily. Laboratory tests provided include fasting plasma glucose, HbA 1C , standard biochemistry, standard hematology, lipid profile, c-peptide, urinalysis, and fasting insulin level. ECG, physical exam, vital signs, and body mass index will also be performed.